Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial

Introduction Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. Ho...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Hervé Devilliers, Maxime Samson, Bernard Bonnotte, Isabelle Fournel, Abderrahmane Bourredjem, Claudie Cladière, Maud Carpentier, Camille Fleck, Amelie Cransac, Marion Cortier, Emilie Galizzi, Marion Brayer, Jean-Louis Alberini
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2025-10-01
Serija:	BMJ Open
Online dostop:	https://bmjopen.bmj.com/content/15/10/e108115.full
Oznake:	Označite Brez oznak, prvi označite!